Indian pharmaceutical major Cipla on 8 September 2014 announced a commercial collaboration with UK-based S&D Pharma to distribute its products in the Czech Republic and Slovakia.
Details of the collaborative agreement
• Under the collaboration, Cipla will be drive its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.
• S&D Pharma will physically distribute all products including respiratory products.
After regulatory approvals, Cipla would launch the Salmeterol-Fluticasone fixed combination inhaler in Czech Republic and Slovakia under the name Fullhale.
The combination inhaler was already launched in Germany under the name Serroflo as well as in Sweden where the combination was launched as Salmeterol-Fluticasone Cipla.
Cipla is one of the global leaders in respiratory medicines with its range of drugs and devices sold in over 100 countries. It was incorporated in 1935.
Dr. Yusuf K. Hamied is the chairman of Cipla who was honoured with Padmabhushan Award in the year 2005.
S&D Pharma represents global pharmaceutical companies and manages the promotion and distribution of their products in Central Europe.
With its head office in United Kingdom, S&D Pharma operates in three other regions including Czech Republic, Slovakia and Bulgaria.
When: 8 September 2014
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.